The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors
Open Access
- 15 December 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (24), 8782-8788
- https://doi.org/10.1158/1078-0432.ccr-05-1664
Abstract
The aim of antitumor immunotherapy is to induce CTL responses against autologous tumors. Previous work has shown that fusion of human dendritic cells and autologous tumor cells induce CTL responses against autologous tumor cells in vitro. However, in the clinical setting of patients with colorectal carcinoma, a major difficulty is the preparation of sufficient amounts of autologous tumor cells. In the present study, autologous dendritic cells from patients with colorectal carcinoma were fused to allogeneic colorectal tumor cell line, COLM-6 (HLA-A2−/HLA-24−), carcinoembryonic antigen (CEA)+, and MUC1+ as an alternative strategy to deliver shared colorectal carcinoma antigens to dendritic cells. Stimulation of autologous T cells by the fusion cells generated with autologous dendritic cells (HLA-A2+ and/or HLA-A24+) and allogeneic COLM-6 resulted in MHC class I– and MHC class II–restricted proliferation of CD4+ and CD8+ T cells, high levels of IFN-γ production in both CD4+ and CD8+ T cells, and the simultaneous induction of CEA- and MUC1-specific CTL responses restricted by HLA-A2 and/or HLA-A24. Finally, CTL induced by dendritic cell/allogeneic COLM-6 fusion cells were able to kill autologous colorectal carcinoma by HLA-A2- and/or HLA-A24-restricted mechanisms. The demonstration of CTL activity against shared tumor-associated antigens using an allogeneic tumor cell line, COLM-6, provides that the presence of alloantigens does not prevent the development of CTL with activity against autologous colorectal carcinoma cells. The fusion of allogeneic colorectal carcinoma cell line and autologous dendritic cells could have potential applicability to the field of antitumor immunotherapy through the cross-priming against shared tumor antigens and provides a platform for adoptive immunotherapy.Keywords
This publication has 15 references indexed in Scilit:
- Repopulation of cancer cells during therapy: an important cause of treatment failureNature Reviews Cancer, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Advanced microscopy solutions for monitoring the kinetics and dynamics of drug?DNA targeting in living cellsAdvanced Drug Delivery Reviews, 2005
- Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiationRole of oxygenation, angiopoietin-1, and matrix metalloproteinasesCancer Cell, 2004
- Microregional Effects of Gemcitabine in HCT-116 XenograftsCancer Research, 2004
- Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in TumorsCancer Research, 2004
- Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cellsBiochemical Journal, 2003
- Repopulation of tumour cells between cycles of chemotherapy: a neglected factorThe Lancet Oncology, 2000
- Comparative activity of doxorubicin and its major metabolite, doxorubicinol, onExperimental and Molecular Pathology, 1991
- Growth of Tumor Cells with Different Sensitivities for Murine Natural Killer Cells in Young and Adult Athymic Nude MicePathobiology, 1985